Figure 7.

Sunitinib modulates pro-angiogenic monocytes in murine tumors. Balb/c mice were grafted subcutaneously with CT-26 tumor cells (0.2 × 10⁵ cells). When the tumors reached 9–10 mm², mice were treated with sunitinib by oral gavage at 40 mg/kg daily or dimethylsulfoxide (DMSO) 10% in PBS. Mice were sacrificed at D20 post tumor graft. Analyses of Tie2⁺ VEGFR-1⁺ CD11b myeloid cells by flow cytometry in blood (A,B) and in tumors (C,D) are shown. Triangles and circles correspond to mice treated by DMSO and sunitinib respectively. Data are representative of two independent experiments with 5 mice/group. Data are mean ±SEM. Difference between the two groups were analyzed using with the Mann-whitney t-test. ** p < 0.01.